#United States #New York #Levi & Korsinsky #Zoetis #ZTS

Zoetis Inc. Faces Class Action Lawsuit Over Allegedly Misleading Statements

Overview
Zoetis Inc. (NYSE: ZTS), a leading animal health company, has found itself under scrutiny as a securities class action lawsuit is pending. This follows claims that the company, along with its top executives, made misrepresentations regarding the performance of its products targeted at companion animals. As shareholders witness a significant decline in stock value, they are encouraged to participate in the class action led by Levi & Korsinsky, LLP.

Key Events
On May 7, 2026, Zoetis shares plummeted by 21.5% after corrective disclosures were made public, resulting in a closing price of $87.31 per share. These disclosures highlighted potential discrepancies between reported product performance and actual market trends, sparking concerns among investors. As a response to ongoing turmoil, the deadline to apply for a lead plaintiff in the ongoing litigation has been set for July 27, 2026. This class action primarily affects those who held shares from January 14, 2025, to May 6, 2026.

Defendants Identified
The lawsuit targets key individuals at Zoetis: CEO Kristin Peck and CFO Wetteny Joseph. Both executives are accused of endorsing misleading information regarding the growth potential of key products while being privy to internal data contradicting their public statements. The lawsuit references that both Peck and Joseph were responsible for preparing and disseminating information regarding the company’s earnings and product performance. This included appearances at investor conferences and earnings calls where the alleged misleading statements were made.

Legal Framework
According to Section 20(a) of the Securities Exchange Act of 1934, those who hold controlling positions can be held liable for violations committed by the company. In this instance, the complaint asserts that Peck and Joseph had not only control over Zoetis’ communications but also the obligation to ensure the accuracy of the information presented to the public and shareholders according to the Sarbanes-Oxley Act. Each executive had certified the truthfulness of the company's SEC filings; however, it is claimed that they were aware or reckless in disregarding the negative trends associated with their flagship products.

Concerns Among Investors
The crux of the issue lies in the advisers' supposed oversight in reporting decreased adoption rates of the product Librela due to safety warnings, coupled with Simparica Trio losing market share to cheaper alternatives. These concerns have led shareholders to believe they have been misled, prompting the call for action among investors to seek accountability and recovery for their losses through this class action.

Steps for Affected Investors
Investors who suffered losses during the specified period are encouraged to gather necessary brokerage records, including purchase dates, the number of shares, and prices. Those interested are invited to contact Levi & Korsinsky for a complimentary evaluation of their eligibility to join the lawsuit. It is important to note that individuals who sold their shares during the class period may still qualify to recover losses based on their initial purchase dates rather than current share ownership.

Conclusion
The ongoing developments surrounding Zoetis have raised serious questions regarding executive accountability and shareholder rights. As the class action progresses, investors are urged to take prompt action, either by joining the lawsuit or seeking advice on their rights. This class action not only seeks to address the losses endured by shareholders but also reinforces the fundamental principle that corporate officers must ensure transparency and accuracy in their communications.

For further inquiries, investors can reach out to Levi & Korsinsky, LLP for more information on how to participate and protect their interests in this unfolding case.